Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.52 |
| ▸ | MPO | P05164 | 3/20 | 0.44 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.43 |
| ▸ | DAO | P14920 | 3/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5538107 | 0.88 | TAAR1 (0.56) | TAAR1MPOAOC3DAOLMNA | |
| SCHEMBL3246283 | 0.85 | TAAR1 (0.35) | TAAR1MPOSLC6A4 | |
| SCHEMBL2139391 | 0.81 | TAAR1 (0.50) | TAAR1AOC3DAOLMNAIDO1 | |
| SCHEMBL30660239 | 0.80 | TAAR1 (0.68) | TAAR1MPOAOC3DAOLMNA | |
| SCHEMBL1151470 | 0.80 | TAAR1 (0.52) | TAAR1MPOAOC3DAOSLC6A4 | |
| SCHEMBL11192733 | 0.78 | GABRA1 (0.44) | — | |
| SCHEMBL1047480 | 0.77 | TAAR1 (0.58) | TAAR1MPOAOC3DAOLMNA | |
| SCHEMBL3244838 | 0.76 | SIGMAR1 (0.39) | L3MBTL1 | |
| SCHEMBL96897 | 0.76 | LIPG (0.43) | — | |
| SCHEMBL3245739 | 0.76 | TAAR1 (0.50) | TAAR1AOC3DAOSLC6A4IDO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8362252-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-29 | — | — | US | disclosed |
| EP-1797082-B1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2012-08-29 | — | — | EP | disclosed |
| EP-2426128-A1 | Carbostyril compound | Otsuka Pharmaceutical Co., Limited (JP) | 2012-03-07 | — | — | EP | disclosed |
| CN-101068810-B | Carbostyril compound | OTSUKA PHARMA CO LTD | 2011-02-09 | — | — | CN | disclosed |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. | 2010-10-14 | — | — | US | disclosed |
| US-7777038-B2 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2010-08-17 | — | — | US | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090326008-A1 | NF-kappa B Inhibitor | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2009-12-31 | — | — | US | disclosed |
| EP-2043644-A1 | NF- B INHIBITOR | Otsuka Pharmaceutical Co., Ltd. (JP) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008010601-A1 | NF- ϰB INHIBITOR | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2008-01-24 | — | — | WO | disclosed |
| US-20070179173-A1 | Carbostyril compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-02 | — | — | US | disclosed |
| EP-1797082-A1 | CARBOSTYRIL COMPOUND | Otsuka Pharmaceutical Company, Limited (JP) | 2007-06-20 | — | — | EP | disclosed |
| WO-2006035954-A1 | CARBOSTYRIL COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-04-06 | — | — | WO | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| EP-0987248-B1 | Amide derivatives and their therapeutic use | WELLCOME FOUND (GB) | 2002-09-04 | — | — | EP | disclosed |
| EP-0987248-A1 | Amide derivatives and their therapeutic use | THE WELLCOME FOUNDATION LIMITED (GB) | 2000-03-22 | — | — | EP | disclosed |
| EP-0126635-B1 | NOVEL OXINDOLE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1991-12-18 | — | — | EP | disclosed |
| US-4694017-A | 2-amido 3(oxindol-3-yl)propionic acids having antiulcer activity | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1987-09-15 | — | — | US | disclosed |
| EP-0126635-A2 | Novel oxindole derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 1984-11-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090326008-A1 | NF-kappa B Inhibitor | NFKBIA, NFKB2, IKBKB | TAAR1 3793/4885MPO 1178/4885AOC3 3400/4885 |
| US-20070179173-A1 | Carbostyril compound | GTF2F1, F3, GTF2F2 | TAAR1 2154/4885MPO 2486/4885AOC3 3669/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | TAAR1 436/4885MPO 1145/4885AOC3 662/4885 |
| US-20100261705-A1 | CARBOSTYRIL COMPOUND | GTF2F1, F3, GTF2F2 | TAAR1 2154/4885MPO 2486/4885AOC3 3669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.